Metastatic Colorectal Cancer Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Metastatic Colorectal Cancer remains an active clinical development field. The competitive center of gravity is moving toward biomarker-defined populations, rational combinations, earlier treatment lines and evidence that can survive active-comparator scrutiny. The PatSnap evidence set used here contains 744 matched trial records and 2,148 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07700719 | SHR-A1904 | Phase 2; Not yet recruiting | Sponsor not listed | China | Incidence of treatment related adverse event [Safety and Tolerability] (From the initiation of the first dose to 90 days after the last dose); Objective response rate (ORR) (From enrollment to the end of treatment at 6 weeks) | 2027-11-28 |
| NCT07691489 | Fam-trastuzumab deruxtecan-NXKI | Phase 2; Not yet recruiting | Memorial Sloan Kettering Cancer Center | United States | Overall Response Rate (ORR) (Up to 1 year) | 2029-06-01 |
| NCT07693751 | SOT-109 | Phase 1/2; Not yet recruiting | SOTIO Biotech as | United States, Moldova | Part A: Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SOT109 (At the end of Cycle 1 (one cycle is 21 days)); Part B: Optimal dose of SOT109 for subsequent clinical trials (Cycle 1 Day 1 up to 30 days after the last dose (each cycle is 21 days)) | 2027-11-29 |
| NCT07688148 | TAX-2 | Phase 1/2; Not yet recruiting | Apmonia Therapeutics SAS | Belgium, France | Number of patients with DLTs _ Phase 1 (From enrollment to the end of Cycle 1 (each cycle is 28 days)); Safety and tolerability to be determined based on the frequency and number of patients with AEs (From enrollment to the end of Cycle 1 (each cycle is 28 days)) | 2029-02-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNDX-5613 in Patients With Colorectal Cancer and Other Solid Tumors (Phase 1/2): the indexed record reports -; -; Phase 1a: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) = 0 Participants.
- A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer (Phase 1/2): the indexed record reports -; -; -.
- The Role of Neutrophil Mitochondrial Dysfunction in Medical Rehabilitation During Palliative Chemotherapy for Metastatic Colorectal Cancer (Phase 2/3): the indexed record reports Relative Dose Intensity of FOLFOX(Mean) = 59.7 percentage (Standard Deviation, 18.9); -; Relative Dose Intensity of FOLFOX(Mean) = 78.4 percentage (Standard Deviation, 15.2).
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including SHR-A1904 (Phase 3; CLDN18.2), Fam-trastuzumab deruxtecan-NXKI (Approved; HER2 x Top I), SOT-109 (Phase 1/2; CDH17 x Top I), TAX-2 (Phase 1/2; CD47 x IFNγ x THBS1). Company & Deal Intelligence records identify sponsor context for Memorial Sloan Kettering Cancer Center, SOTIO Biotech as, Apmonia Therapeutics SAS. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Prospective biomarker thresholds that predict benefit rather than simply confirm target presence.
- Randomized sequencing evidence after prior targeted therapy, immunotherapy or antibody–drug conjugates.
- Endpoints that connect response depth with durability, quality of life and overall survival.
- Geographically broader development programs with harmonized molecular testing.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Metastatic Colorectal Cancer has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
